Home Neoplasma 2018 Neoplasma Vol.65, No.2, p.192-200, 2018

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.2, p.192-200, 2018

Title: MicroRNA-30b inhibits non-small cell lung cancer cell growth by targeting the epidermal growth factor receptor
Author: Z. QI, B. ZHANG, J. ZHANG, Q. HU, F. XU, B. CHEN, C. ZHU

Abstract: Lung cancer, especially non-small cell lung cancer (NSCLC), is the leading cause of cancer-related mortality in the world. Both microRNAs and epidermal growth factor receptor (EGFR) are important factors in NSCLC. In our study, the expression of miR-30b in 47 tumor tissues and paired normal tissues of NSCLC were detected by RT-PCR, and we found that miR-30b was down-regulated in NSCLC tumor tissues and was associated with TNM stage, differentiation, and lymph node metastases. Then we investigated the ability of miR-30b to regulate EGFR in several NSCLC cell lines, and found that miR-30b inhibited proliferation, migration and invasion, induced apoptosis and enhanced sensitivity of the NSCLC cells to EGFR tyrosine kinase inhibitors (EGFR-TKIs) by targeting EGFR and repressing EGFR signaling pathways. Overall, these results indicate that miR-30b may be a potential therapeutic target in NSCLC patients.

Keywords: miR-30b, non-small cell lung cancer, EGFR, proliferation, apoptosis
Published online: 13-Mar-2018
Year: 2018, Volume: 65, Issue: 2 Page From: 192, Page To: 200
doi:10.4149/neo_2018_170217N118
Price: 21.60 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.